Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.

Patrick R Merz, Nina Röckel,Seda Ballikaya,Gerd U Auffarth,Ingo Schmack

BMC ophthalmology（2018）

引用 8|浏览8

暂无评分

摘要

In this study, the anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®) demonstrated no cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas over the limited study time period of 4 weeks. However, based on the study design (in-vitro) and the limited follow-up period, no conclusions on potential long-term effects can be drawn.

查看译文

关键词

Bevacizumab,Corneal angiogenesis,Corneal endothelial cells,Corneal neovascularization,Ranibizumab,Vascular endothelial growth factor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要